NRDE2 deficiency impairs homologous recombination repair and sensitizes hepatocellular carcinoma to PARP inhibitors

被引:1
|
作者
Wang, Yahui [1 ,2 ]
Liu, Xinyi [1 ]
Zuo, Xianbo [3 ]
Wang, Cuiling [1 ]
Zhang, Zheng [1 ]
Zhang, Haitao [1 ]
Zeng, Tao [4 ]
Chen, Shunqi [1 ]
Liu, Mengyu [1 ]
Chen, Hongxia [1 ]
Song, Qingfeng [5 ]
Li, Qi [1 ,6 ]
Yang, Chenning [1 ]
Le, Yi [7 ]
Xing, Jinliang [8 ]
Zhang, Hongxin [2 ,9 ]
An, Jiaze [10 ]
Jia, Weihua [11 ,12 ]
Kang, Longli [13 ]
Zhang, Hongxing [6 ]
Xie, Hui [14 ]
Ye, Jiazhou [15 ]
Wu, Tianzhun [15 ]
He, Fuchu [2 ]
Zhang, Xuejun [16 ,17 ]
Li, Yuanfeng [1 ]
Zhou, Gangqiao [1 ,18 ]
机构
[1] Beijing Inst Radiat Med, Natl Ctr Prot Sci Beijing, Beijing Proteome Res Ctr, State Key Lab Med Prote, Beijing, Peoples R China
[2] Beijing Inst Lifeom, Natl Ctr Prot Sci Beijing, Beijing Proteome Res Ctr, State Key Lab Med Prote, Beijing, Peoples R China
[3] China Japan Friendship Hosp, Dept Dermatol, Dept Pharm, Beijing, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Fac Hepatobiliary Pancreat Surg, Med Ctr 1, Beijing, Peoples R China
[5] Guangxi Med Univ, Affiliated Canc Hosp, Nanning, Guangxi, Peoples R China
[6] Univ South China, Sch Med, Dept Neurosci, Hengyang, Hunan, Peoples R China
[7] Chinese Peoples Liberat Army Gen Hosp, Dept Hepatobiliary Surg, Med Ctr 5, Beijing, Peoples R China
[8] Air Force Med Univ, Expt Teaching Ctr Basic Med, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China
[9] Air Force Med Univ, Tangdu Hosp, Dept Pain Treatment, Xian, Shaanxi, Peoples R China
[10] Air Force Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian, Shaanxi, Peoples R China
[11] State Key Lab Oncol Southern China, Guangzhou, Guangdong, Peoples R China
[12] Sun Yat Sen Univ, Dept Expt Res, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[13] Xizang Minzu Univ, Sch Med, Key Lab Mol Genet Mech & Intervent Res High Altitu, Key Lab High Altitude Environm & Genes Related Dis, Xianyang, Shaanxi, Peoples R China
[14] Chinese Peoples Liberat Army Gen Hosp, Dept Intervent Oncol, Med Ctr 5, Beijing, Peoples R China
[15] Guangxi Med Univ, Guangxi Liver Canc Diag & Treatment Engn & Technol, Dept Hepatobiliary & Pancreat Surg, Canc Hosp, Nanning, Guangxi, Peoples R China
[16] Anhui Med Univ, Affiliated Hosp 1, Dept Dermatol, Hefei, Anhui, Peoples R China
[17] Anhui Med Univ, Affiliated Hosp 1, Inst Dermatol, Hefei, Anhui, Peoples R China
[18] Nanjing Med Univ, Collaborat Innovat Ctr Personalized Canc Med, Ctr Global Hlth, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
来源
CELL GENOMICS | 2024年 / 4卷 / 05期
基金
中国国家自然科学基金;
关键词
GENOME-WIDE ASSOCIATION; DNA-REPAIR; SUSCEPTIBILITY LOCUS; READ ALIGNMENT; CANCER; EXPRESSION; NBS1; PATHOGENICITY; POLYMORPHISM; FRAMEWORK;
D O I
10.1016/j.xgen.2024.100550
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To identify novel susceptibility genes for hepatocellular carcinoma (HCC), we performed a rare -variant association study in Chinese populations consisting of 2,750 cases and 4,153 controls. We identified four HCCassociated genes, including NRDE2 , RANBP17 , RTEL1 , and STEAP3 . Using NRDE2 (index rs199890497 [p.N377I], p = 1.19 3 10 - 9 ) as an exemplary candidate, we demonstrated that it promotes homologous recombination (HR) repair and suppresses HCC. Mechanistically, NRDE2 binds to the subunits of casein kinase 2 (CK2) and facilitates the assembly and activity of the CK2 holoenzyme. This NRDE2-mediated enhancement of CK2 activity increases the phosphorylation of MDC1 and then facilitates the HR repair. These functions are eliminated almost completely by the NRDE2-p.N377I variant, which sensitizes the HCC cells to poly(ADP-ribose) polymerase (PARP) inhibitors, especially when combined with chemotherapy. Collectively, our findings highlight the relevance of the rare variants to genetic susceptibility to HCC, which would be helpful for the precise treatment of this malignancy.
引用
收藏
页数:34
相关论文
共 50 条
  • [1] CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
    Lu, Xue
    He, Yaowu
    Johnston, Rebecca L.
    Nanayakarra, Devathri
    Sankarasubramanian, Sivanandhini
    Lopez, J. Alejandro
    Friedlander, Michael
    Kalimutho, Murugan
    Hooper, John D.
    Raninga, Prahlad V.
    Khanna, Kum Kum
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)
  • [2] CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
    Xue Lu
    Yaowu He
    Rebecca L. Johnston
    Devathri Nanayakarra
    Sivanandhini Sankarasubramanian
    J. Alejandro Lopez
    Michael Friedlander
    Murugan Kalimutho
    John D. Hooper
    Prahlad V. Raninga
    Kum Kum Khanna
    Journal of Experimental & Clinical Cancer Research, 41
  • [3] hMOB2 deficiency impairs homologous recombination-mediated DNA repair and sensitises cancer cells to PARP inhibitors
    Gundogdu, Ramazan
    Erdogan, M. Kadir
    Ditsiou, Angeliki
    Spanswick, Victoria
    Garcia-Gomez, Juan Jose
    Hartley, John A.
    Esashi, Fumiko
    Hergovich, Alexander
    Gomez, Valenti
    CELLULAR SIGNALLING, 2021, 87
  • [4] Homologous recombination deficiency and PARP inhibitors in therapeutics
    Salaun, Helene
    Saint-Ghislain, Mathilde
    Bellesoeur, Audrey
    Beuzeboc, Philippe
    Neuzillet, Cindy
    Dieras, Veronique
    Stern, Marc Henri
    Rodrigues, Manuel
    BULLETIN DU CANCER, 2022, 109 (01) : 76 - 82
  • [5] Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors
    Wang, Junhui
    Ding, Qianshan
    Fujimori, Hiroaki
    Motegi, Akira
    Miki, Yoshio
    Masutani, Mitsuko
    ONCOTARGET, 2016, 7 (07) : 7701 - 7713
  • [6] Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair
    Xiao, Yinan
    Wu, Yu
    Wang, Qilong
    Li, Mo
    Deng, Chaolin
    Gu, Xiaoyang
    CELL COMMUNICATION AND SIGNALING, 2025, 23 (01)
  • [7] Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors
    Zhihai Wang
    Wenqi Zuo
    Quan Zeng
    Yi Qian
    Yanshi Li
    Chuan Liu
    Jue Wang
    Shixun Zhong
    Youquan Bu
    Guohua Hu
    Journal of Biomedical Science, 26
  • [8] Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors
    Wang, Zhihai
    Zuo, Wenqi
    Zeng, Quan
    Qian, Yi
    Li, Yanshi
    Liu, Chuan
    Wang, Jue
    Zhong, Shixun
    Bu, Youquan
    Hu, Guohua
    JOURNAL OF BIOMEDICAL SCIENCE, 2019, 26
  • [9] Inhibition of phosphoprotein phosphatase 2A (PP2A) sensitizes pancreatic cancer to PARP inhibitors by modulation of homologous recombination repair
    Elgenaidi, I.
    Lowery, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S263 - S263
  • [10] Arsenic compound sensitizes homologous recombination proficient ovarian cancer to PARP inhibitors
    Xu, Junfen
    Shen, Yuanming
    Wang, Conghui
    Tang, Sangsang
    Hong, Shiyuan
    Lu, Weiguo
    Xie, Xing
    Cheng, Xiaodong
    CELL DEATH DISCOVERY, 2021, 7 (01)